MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET T: 617.491.9700 F: 617.621.0431Momenta Pharmaceuticals Inc • August 9th, 2007 • Biological products, (no disgnostic substances)
Reference is made to the Amended and Restated Exclusive Patent License between the Massachusetts Institute of Technology and Momenta Pharmaceuticals, Inc. dated November 1, 2002, as amended by a First Amendment dated November 15, 2002, letter agreements dated September 12, 2003 and October 22, 2003, a Second Amendment dated November 19, 2003, a Third Amendment dated April 2, 2004, a Fourth Amendment dated July 17, 2004, a Fifth Amendment dated August 5, 2006, a Sixth Amendment dated January 10, 2007 and letter agreements dated August 10, 2006 and October 18, 2006 (collectively, the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings given such terms in the Agreement.
COLLABORATION AND LICENSE AGREEMENT By and Among Momenta Pharmaceuticals, Inc. and Sandoz AGCollaboration and License Agreement • August 9th, 2007 • Momenta Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Collaboration and License Agreement (“Agreement”) is entered into as of this 13th day of June, 2007 (“Effective Date”), by and between Momenta Pharmaceuticals, Inc., a Delaware corporation (“Momenta”) with a principal place of business at 675 West Kendall Street, Cambridge, MA 02142, and Sandoz AG, a Swiss corporation (“Sandoz”) with a principal place of business at Lichtstraße 35, CH 4056 Basel BS, Switzerland.
